

# ASCO 2021 Annual Meeting

June 4-8, 2021

Authors	Title	Presentation Type	Session	Link
<p>Julius Strauss, <b>Fadi S. Braiteh</b>, Emiliano Calvo, Maria De Miguel, Andres Cervantes, <b>William Jeffery Edenfield</b>, Tianhong Li, Marika Anna Rasschaert, Tjong-Won Park-Simon, Federico Longo, Luis G. Paz-Ares, <b>Alexander I. Spira</b>, Genevieve Jehl, Isabelle Dussault, Laureen S. Ojalvo, James L. Gulley, Suzanne Wendy Allan;</p> <p>Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, Spain; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Greenville Hospital System University Medical Center (ITOR), Greenville, SC; University of California Davis Comprehensive Cancer Center, Sacramento, CA; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medizinische Hochschule Hannover, Hannover, Germany; Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRICYS), CIBERONC, Madrid, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Merck KGaA, Darmstadt, Germany; EMD Serono Research &amp; Development Institute, Inc., Billerica, MA; Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Tasman Oncology Research Ltd, Southport, Queensland, Australia</p>	<p>Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-<math>\beta</math> and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies.</p>	<p>Clinical Science Symposium</p>	<p>At Your Cervix: Building on Immunotherapy for Treatment of Recurrent Cervical Cancer</p>	<p><a href="https://meetinglibrary.asco.org/record/195556/abstract">https://meetinglibrary.asco.org/record/195556/abstract</a></p>
<p>Linda R. Mileskin, Kathleen N. Moore, Elizabeth Barnes, Val GebSKI, Kailash Narayan, Nathan Bradshaw, Yeh Chen Lee, Katrina Diamante, Anthony W. Fyles, William Small, David K. Gaffney, Pearly Khaw, Susan Brooks, J Spencer Thompson, Warner King Huh, Matthew Carlson, Cara Amanda Mathews, Danny Rischin, Martin R. Stockler, <b>Bradley J. Monk</b>;</p> <p>Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Stephenson Cancer Center, Oklahoma City, OK; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; NCIC-CTG, Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada; Loyola University Medical Center, Maywood, IL; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Auckland Hospital, Auckland, New Zealand; Univ of Oklahoma Health Sci Ctr, Oklahoma City, OK; University of Alabama at Birmingham, Birmingham, AL; The University of Texas Southwestern Medical Center, Dallas, TX; Program in Women's Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ</p>	<p>Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).</p>	<p>Late Breaking Abstract</p>	<p>Plenary Session</p>	

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

Authors	Title	Presentation Type	Session	Link
<p>Jennifer Keating Litton, Joseph Thaddeus Beck, Jason M. Jones, <b>Jay Andersen, Joanne Lorraine Blum</b>, Lida A. Mina, Raymond Brigg, <b>Michael A. Danso</b>, Yuan Yuan, Antonello Abbattista, Kay Noonan, Jayeta Chakrabarti, Akos Czibere, William Fraser Symmans, Melinda L. Telli;</p> <p>The University of Texas MD Anderson Cancer Center, Houston, TX; Highlands Oncology Group, Springdale, AR; Avera Cancer Institute, Sioux Falls, SD; Compass Oncology, West Cancer Center, Tigard, OR; Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX; Banner MD Anderson Cancer Center, Gilbert, AZ; Brigg Center for Cancer Care and Survivorship, Knoxville, TN; Virginia Oncology Associates, Norfolk, VA; City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Pfizer Oncology, Milan, Italy; Pfizer Inc., Groton, CT; Pfizer Inc., Walton Oaks, United Kingdom; Pfizer Inc., Cambridge, MA; Stanford University School of Medicine, Stanford, CA</p>	<p>Neoadjuvant talazoparib in patients with germline <i>BRCA1/2</i> (<i>gBRCA1/2</i>) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.</p>	Oral	Breast Cancer—Metastatic	<a href="https://meetinglibrary.asco.org/record/196833/abstract">https://meetinglibrary.asco.org/record/196833/abstract</a>
<p>Joshua Bauml, Byoung Chul Cho, Keunchil Park, Ki Hyeong Lee, EUN KYUNG CHO, Dong-Wan Kim, Sang-We Kim, Eric B. Haura, Joshua K. Sabari, Rachel E. Sanborn, Misako Nagasaka, Sai-Hong Ignatius Ou, Anna Rachel Minchom, Jorge E. Gomez, Joshua C. Curtin, Grace Gao, Amy Roshak, Meena Thayu, Roland Elmar Knoblauch, <b>Alexander I. Spira</b>;</p> <p>Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Samsung Medical Center at Sungkyunkwan University School of Medicine, Seoul, South Korea; Chungbuk National University Hospital, Cheongju, South Korea; Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea; Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; New York University School of Medicine, New York, NY; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; Karmanos Cancer Institute, Detroit, MI; University of California Irvine, Orange, CA; Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, United Kingdom; Icahn School of Medicine at Mount Sinai, New York, NY; Janssen R&amp;D, Spring House, PA; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA</p>	<p>Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.</p>	Oral	Lung Cancer—Non-Small Cell Metastatic	<a href="https://meetinglibrary.asco.org/record/196820/abstract">https://meetinglibrary.asco.org/record/196820/abstract</a>
<p><b>Nicholas J. Robert, Esmond D. Nwokeji, Janet L. Espirito, Liwei Chen, Mandar Karhade, Makenzi Colleen Evangelist, Alexander I. Spira, Marcus A. Neubauer, Susie A. Bullock, Robert L. Coleman</b>, on behalf of</p> <p>MYLUNG Consortium Collaborators: The U.S. Oncology Network and sponsors; Ontada, Irving, TX; US Oncology Research / New York Oncology Hematology, Albany, NY; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; US Oncology Research/The US Oncology Network, The Woodlands, TX; US Oncology Research, The Woodlands, TX</p>	<p>Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.</p>	Oral	Lung Cancer—Non-Small Cell Metastatic	<a href="https://meetinglibrary.asco.org/record/197070/abstract">https://meetinglibrary.asco.org/record/197070/abstract</a>
<p><b>Anthony W. Tolcher</b>, James Andrew Reeves, Meredith McKean, Bartosz Chmielowski, Joseph Thaddeus Beck, Montaser F. Shaheen, Neeta Somaiah, Melissa Wilson, <b>Alexander I. Spira</b>, Joseph J. Drabick, Yuefen Tang, Robert Winkler, Mingyu Li, Mohammad Ahmad, Ming Lu, Zhiyan Liang, Dajun Yang, Yifan Zhai;</p> <p>Texas Oncology-San Antonio Babcock, San Antonio, TX; Florida Cancer Specialists South/Sarah Cannon Research Institute, Fort Myers, FL; Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Highlands Oncology Group, Springdale, AR; University of Arizona Cancer Center, Tucson, AZ; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA; Ascentage Pharma Group Inc., Rockville, MD; State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China</p>	<p>Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immunologic (I-O) drugs.</p>	Oral	Developmental Therapeutics—Immunotherapy	<a href="https://meetinglibrary.asco.org/record/196027/abstract">https://meetinglibrary.asco.org/record/196027/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
Rodney Paul Rocconi, Sharad A. Ghamande, <b>Minal A. Barve</b> , Erin E. Stevens, Phylcia Aaron, Laura Stanbery, Ernest Bogner, Luisa Manning, John J. Nemunaitis, David M. O'Malley, Thomas J. Herzog, <b>Bradley J. Monk, Robert L. Coleman</b> , The Vigil Team;  University of South Alabama, Mobile, AL; Georgia Cancer Center, Augusta University, Augusta, GA; Texas Oncology, Dallas, TX; Billings Clinic, Billings, MT; Gradalis, Inc., Carrollton, TX; Gradalis, Inc, Carrollton, TX; Gradalis, Inc., Dallas, TX; The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH; University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati, OH; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ; US Oncology Research, The Woodlands, TX	Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.	Oral	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/196655/abstract">https://meetinglibrary.asco.org/record/196655/abstract</a>
Shannon Neville Westin, <b>Robert L. Coleman</b> , Bryan M. Fellman, Ying Yuan, Anil K. Sood, Pamela T. Soliman, Alexi A. Wright, Neil S. Horowitz, Susana M. Campos, Panagiotis A. Konstantinopoulos, Charles F. Levenback, David Marc Gershenson, Karen H. Lu, Virginia Bayer, Sobiya Tukdi, Alexis Rabbit, Lone Ottesen, Robert Godin, Gordon B. Mills, Joyce F. Liu;  The University of Texas MD Anderson Cancer Center, Houston, TX; US Oncology Research, The Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Cambridge, United Kingdom; AstraZeneca, Waltham, MA; Oregon Health & Science University, Portland, OR	EFFORT: Efficacy Of adavosertib in parp Resistance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.	Oral	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/195547/abstract">https://meetinglibrary.asco.org/record/195547/abstract</a>
<b>Nicholas J. Robert, Esmond D. Nwokeji, Janet L. Espirito, Liwei Chen, Mandar Karhade, Makenzi Colleen Evangelist, Alexander I. Spira, Marcus A. Neubauer, Susie A. Bullock, Robert L. Coleman</b> , on behalf of MYLUNG Consortium Collaborators: The U.S. Oncology Network and sponsors;  Ontada, Irving, TX; US Oncology Research / New York Oncology Hematology, Albany, NY; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; US Oncology Research/The US Oncology Network, The Woodlands, TX; US Oncology Research, The Woodlands, TX"	Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.	Oral	Lung Cancer—Non-Small Cell Metastatic	<a href="https://meetinglibrary.asco.org/record/197070/abstract">https://meetinglibrary.asco.org/record/197070/abstract</a>
Carlo Palmieri, Hannah M. Linden, Stephen Birrell, Elgene Lim, Lee S. Schwartzberg, Hope S. Rugo, Patrick Wayne Cobb, Kirti Jain, Charles L. Vogel, <b>Joyce O'Shaughnessy</b> , Stephen R. D. Johnston, Robert H. Getzenberg, K. Gary Barnette, Mitchell S. Steiner, Adam Brufsky, Beth Overmoyer;  Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom; University of Washington Medical Center, Seattle Cancer Care Alliance, Seattle, WA; Wellend Health/Burnside Hospital, Toorak Gardens, Australia; Olivia Newton John Cancer & Wellness Centre, Heidelberg, Australia; West Cancer Center, Memphis, TN; University of California, San Francisco, San Francisco, CA; Frontier Cancer Center, Billings, MT; Ashland Bellefonte Cancer Ctr, Ashland, KY; Sylvester At Deerfield Beach, Deerfield Beach, FL; Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Veru Inc., Miami, FL; GTX, Inc., Memphis, TN; NSABP/NRG Oncology, and the UPMC Hillman Cancer Center, Pittsburgh, PA; Dana-Farber Cancer Institute, Boston, MA	Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.	Poster Discussion Session	Breast Cancer—Metastatic	<a href="https://meetinglibrary.asco.org/record/195739/abstract">https://meetinglibrary.asco.org/record/195739/abstract</a>
Tomasz M. Beer, Charles H. McDonnell, Lincoln Nadauld, Minetta C. Liu, Eric A. Klein, <b>Robert Lawrence Reid</b> , Catherine Marinac, Karen Chung, Margarita Lopatin, Eric T. Fung, Deborah Schrag;  Knight Cancer Institute, Oregon Health & Science University, Portland, OR; Sutter Health, Sacramento, CA; Intermountain Healthcare, St. George, UT; Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; US Oncology Research, Virginia Cancer Specialists, Fairfax, VA; Dana-Farber Cancer Institute, Boston, MA; GRAIL, Inc., Menlo Park, CA	Interim results of PATHFINDER, a clinical use study using a methylation-based multi-cancer early detection test.	Poster Discussion Session	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	<a href="https://meetinglibrary.asco.org/record/195787/abstract">https://meetinglibrary.asco.org/record/195787/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
<p>Antonio Gonzalez Martin, Ursula A. Matulonis, Jacob Korach, Mansoor Raza Mirza, Kathleen N. Moore, Divya Gupta, Stanislav Lechpammer, <b>Bradley J. Monk</b>;</p> <p>Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Gynecologic Oncology Department, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Division of Obstetrics and Gynecology, Department of Gynecologic Oncology, University of Oklahoma Health Science Center, Stephenson Cancer Center, Oklahoma City, OK; GlaxoSmithKline, Waltham, MA; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ</p>	Niraparib efficacy and safety in patients with <i>BRCA</i> mutated ( <i>BRCAm</i> ) ovarian cancer: Results from three phase 3 niraparib trials.	Poster Discussion Session	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/195563/abstract">https://meetinglibrary.asco.org/record/195563/abstract</a>
<p>Kathryn Finch Mileham, Suanna Steeby Bruinooge, Charu Aggarwal, Alicia L. Patrick, Christiana Davis, Daniel Mesenhowski, <b>Alexander I. Spira, Eric J. Clayton, David Michael Waterhouse</b>, Sue Moore, Abdul-Rahman Jazieh, Ronald C. Chen, Melinda Kaltenbaugh, Jen Hanley Williams, Richard L. Schilsky, Liz Garrett-Mayer;</p> <p>Levine Cancer Institute/Atrium Health, Charlotte, NC; American Society of Clinical Oncology, Alexandria, VA; University of Pennsylvania, Philadelphia, PA; Levine Cancer Institute, Atrium Health, Charlotte, NC; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Virginia Cancer Specialists, Fairfax, VA; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Oncology Hematology Care, Cincinnati, OH; US Oncology Research / Oncology Hematology Care (OHC), Inc., Cincinnati, OH; Virginia Cancer Institute, Richmond, VA; Cincinnati Cancer Advisors, Cincinnati, OH; University of Kansas, Kansas City, KS</p>	Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry.	Poster Discussion Session	Health Services Research and Quality Improvement	<a href="https://meetinglibrary.asco.org/record/196677/abstract">https://meetinglibrary.asco.org/record/196677/abstract</a>
<p><b>Lalan S. Wilfong, Neal Dave, Jody S. Garey, Sara Toth, Jim R. Schwartz, Lance Ortega, Chris Sellers, Barry Don Brooks</b>;</p> <p>Texas Oncology/The US Oncology Network, Dallas, TX; Texas Oncology, Dallas, TX; US Oncology, Houston, TX; Texas Oncology PA, Dallas, TX; US Oncology, The Woodlands, TX</p>	A successful model of biosimilar adoption in a community oncology practice.	Poster Discussion Session	Health Services Research and Quality Improvement	<a href="https://meetinglibrary.asco.org/record/196996/abstract">https://meetinglibrary.asco.org/record/196996/abstract</a>
<p>Howard A. Burris III, <b>Alexander I. Spira</b>, Matthew H. Taylor, Oladapo O. Yeku, Joyce F. Liu, Pamela N. Munster, Erika P. Hamilton, Jacob Stephen Thomas, Frances Gatlin, Richard T. Penson, Thomas Adam Abrams, Mallika Sachdev Dhawan, Jacqueline M. Walling, John W. Frye, Kevin Romanko, Victoria Sung, Carrie Brachmann, Anthony B. El-Khoueiry;</p> <p>Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Providence Cancer Institute, Portland, OR; Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of California San Francisco, San Francisco, CA; Division of Oncology, USC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA; Virginia Cancer Specialist, Fairfax, VA; Harvard Medical School, Massachusetts General Hospital, Boston, MA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Arch Oncology, Brisbane, CA; University of Southern California, Los Angeles, CA</p>	A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.	Poster Discussion Session	Developmental Therapeutics—Immunotherapy	<a href="https://meetinglibrary.asco.org/record/199338/abstract">https://meetinglibrary.asco.org/record/199338/abstract</a>
<p>Michael S. Gordon, Richard D. Carvajal, <b>Alexander I. Spira</b>, Marilyn Huang, Paul Watkins, Ben Powell, Kerry Inokuchi, Michael Sterba, Bernice Matusow, Chelsea Hope, Jason Halladay, Chao Zhang, Jacqueline M. Walling, Athanasios C. Tsiatis, Amita Patnaik;</p> <p>HonorHealth Research Institute, Scottsdale, AZ; Columbia University Irving Medical Center, New York, NY; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Sylvester Comprehensive Cancer Center, Miami, FL; Plexikon Inc., Berkeley, CA; START, San Antonio, TX</p>	Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma.	Poster Discussion Session	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	<a href="https://meetinglibrary.asco.org/record/196671/abstract">https://meetinglibrary.asco.org/record/196671/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
<p>Rachel N. Grisham, Ignace Vergote, Susana N. Banerjee, Esther N. Drill, Michel Fabbro, Mansoor Raza Mirza, Ignacio Romero, <b>Robert L. Coleman</b>, Amit M. Oza, Felix Hilpert, Kathleen N. Moore, Anneke M. Westermann, Carol Aghajanian, Giovanni Scambia, Adam P. Boyd, Jean Cantey-Kiser, David M. O'Malley, John H. Farley, Nicoletta Colombo, <b>Bradley J. Monk</b>;</p> <p>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Belgium and Luxembourg Gynaecological Oncology Group (BCOG), University of Leuven, Leuven Cancer Institute, Leuven, Belgium; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; ICM Val d'Aurelle, Montpellier, France; The Finsen Centre 5073, Copenhagen, Denmark; Instituto Valenciano de Oncología, Valencia, Spain; US Oncology Research, The Woodlands, TX; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Onkologisches Therapiezentrum am Krankenhaus Jerusalem, Hamburg, Germany; Stephenson Cancer Center, Oklahoma City, OK; Amsterdam University Medical Center, Amsterdam, Netherlands; MITO and Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Array BioPharma Inc., Boulder, CO; Biostatistics, PharPoint Research Inc, Durham, NC; The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH; St Joseph's Hospital and Medical Center, a Member of Catholic Healthcare West, Phoenix, AZ; University of Milan-Bicocca and European Institute of Oncology (IEO) IRCCS, Milan, Italy; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ</p>	<p>Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).</p>	<p>Poster Discussion Session</p>	<p>Gynecologic Cancer</p>	<p><a href="https://meetinglibrary.asco.org/record/195548/abstract">https://meetinglibrary.asco.org/record/195548/abstract</a></p>
<p><b>Jeff Porter Sharman</b>, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M. Pagel, Manali K. Kamdar, Talha Munir, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steve E. Coutre, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, William G. Wierda, Priti Patel, Min Hui Wang, John C. Byrd;</p> <p>Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, OR; Somogy County Mór Kaposi General Hospital, Kaposvar, Hungary; Maria Sklodowska-Curie National Institute of Oncology, Krakow, Poland; Novant Health Cancer Institute, Charlotte, NC; Swedish Cancer Institute, Seattle, WA; University of Colorado Cancer Center, Aurora, CO; St James's University Hospital, Leeds, United Kingdom; Tauranga Hospital, Tauranga, New Zealand; Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; Department of Hematology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Max Rady College of Medicine, Winnipeg, MB, Canada; Stanford University School of Medicine, Stanford, CA; Peninsula Health and Peninsula Private Hospital, Melbourne, VIC, Australia; Skåne University Hospital, Lund, Sweden; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; University Hospitals Leuven, Leuven, Belgium; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; AstraZeneca, South San Francisco, CA; The Ohio State University Comprehensive Cancer Center, Division of Hematology, Columbus, OH</p>	<p>Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up.</p>	<p>Poster Discussion Session</p>	<p>Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia</p>	<p><a href="https://meetinglibrary.asco.org/record/196295/abstract">https://meetinglibrary.asco.org/record/196295/abstract</a></p>
<p>Omid Hamid, Ding Wang, Tae Min Kim, Sang-We Kim, Nehal J. Lakhani, Melissa Lynne Johnson, Roman Groisberg, Kyriakos P. Papadopoulos, John M. Kaczmar, Mark R. Middleton, <b>Alexander I. Spira</b>, Stephen K. Williamson, Guilherme Rabinowits, Rodolfo Gutierrez, Meredith McKean, Shuquan Chen, James Cassidy, Jayakumar Mani, Tasha Nicholle Sims, Glenn Kroog;</p> <p>The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA; Henry Ford Hospital, Detroit, MI; Seoul National University Hospital, Seoul, South Korea; University of Ulsan College of Medicine, Seoul, South Korea; START Midwest, Grand Rapids, MI; Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; START-San Antonio, San Antonio, TX; MUSC Hollings Cancer Center, Charleston, SC; University of Oxford, Oxford, United Kingdom; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; University of Kansas Medical Center, Westwood, KS; Miami Cancer Institute/Baptist Health South Florida, Miami, FL; The Angeles Clinical and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA; Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Regeneron Pharmaceuticals, Inc., Tarrytown, NY</p>	<p>Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.</p>	<p>Poster Discussion Session</p>	<p>Melanoma/Skin Cancers</p>	<p><a href="https://meetinglibrary.asco.org/record/195988">https://meetinglibrary.asco.org/record/195988</a></p>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
<p>Jennifer Keating Litton, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, Henri Roche, Kyung-Hun Lee, Annabel Goodwin, Tiziana Usari, Silvana Lanzalone, Carolin Guenzel, <b>Joanne Lorraine Blum</b>, Hope S. Rugo;</p> <p>The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain; Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France; Seoul National University Hospital, Seoul, South Korea; Medical Oncology Department, Concord Repatriation General Hospital, Concord, Australia; Pfizer Oncology, Milan, Italy; Pfizer Oncology, Berlin, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA</p>	<p>Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.</p>	Poster Session	Breast Cancer—Metastatic	<a href="https://meetinglibrary.asco.org/record/198185/abstract">https://meetinglibrary.asco.org/record/198185/abstract</a>
<p>Johannes Ettl, Hope S. Rugo, Sara A. Hurvitz, Miguel Martin, Henri Roche, Kyung-Hun Lee, Annabel Goodwin, Tiziana Usari, Silvana Lanzalone, Carolin Guenzel, <b>Joanne Lorraine Blum</b>, Jennifer Keating Litton;</p> <p>Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain; Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France; Seoul National University Hospital, Seoul, South Korea; Medical Oncology Department, Concord Repatriation General Hospital, Concord, Australia; Pfizer Oncology, Milan, Italy; Pfizer Oncology, Berlin, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX; The University of Texas MD Anderson Cancer Center, Houston, TX</p>	<p>Characterization of long-term responders following treatment with talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 embraca trial.</p>	Poster Session	Breast Cancer—Metastatic	<a href="https://meetinglibrary.asco.org/record/198290/abstract">https://meetinglibrary.asco.org/record/198290/abstract</a>
<p><b>Joyce O'Shaughnessy</b>, Kevin Punie, Mafalda Oliveira, Filipa Lynce, Sara M. Tolaney, Florence Dalenc, Priyanka Sharma, Michaela L. Tsai, Aditya Bardia, Javier Cortes, <b>Michael A. Danso</b>, Stephanie Henry, Alejandra T. Perez, Sara A. Hurvitz, Kevin Kalinsky, Quan Hong, Martin Sebastian Olivo, Loretta Itri, Hope S. Rugo;</p> <p>Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Medical Oncology Department and Breast Cancer Group, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Georgetown Lombardi Comprehensive Cancer Center and Medical Oncology, Dana-Farber Cancer Institute, Washington, DC; Dana-Farber Cancer Institute, Boston, MA; Institut Claudius Regaud-IUCT Oncopole, Toulouse, France; University of Kansas Medical Center, Westwood, KS; VPCI Oncology Research, Minneapolis, MN; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; International Breast Cancer Center, Quiron Group, Madrid &amp; Barcelona, Barcelona, Spain; Virginia Oncology Associates, Norfolk, VA; Department of Oncology-Hematology, Radiotherapy, and Nuclear Medicine, CHU UCL Namur, Namur, Belgium; Department of Medicine, University of Miami Miller School of Medicine, Miami, FL; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Winship Cancer Institute, Emory University, Atlanta, GA; Department of Clinical Development, Immunomedics, Inc, a subsidiary of Gilead Sciences, Inc., Morris Plains, NJ; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA</p>	<p>Assessment of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).</p>	Poster Session	Breast Cancer—Metastatic	<a href="https://meetinglibrary.asco.org/record/198258/abstract">https://meetinglibrary.asco.org/record/198258/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
<p>Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Veronique Dieras, Florence Dalenc, Jennifer Robinson Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, <b>Joyce O'Shaughnessy</b>, Sibylle Loibl, Luca Gianni, Martine J. Piccart-Gebhart, Quan Hong, Martin Sebastian Olivo, Loretta Itri, Javier Cortes;</p> <p>University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Medical Oncology Department and D3i, Institut Curie, Paris, France; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Department of Medical Oncology, Centre Eugene Marquis, Rennes, France; Institut Claudius Regaud-IUCT Oncopole, Toulouse, France; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; Medical Oncology Department, Oncologisch Centrum, UZ Brussel, Brussels, Belgium; Miami Cancer Institute, Miami, FL; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Winship Cancer Institute, Emory University, Atlanta, GA; Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; Department of Medicine and Research, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Gianni Bonadonna Foundation, Milan, Italy; Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium; Department of Clinical Development, Immunomedics, Inc, a subsidiary of Gilead Sciences, Inc., Morris Plains, NJ; International Breast Cancer Center, Quiron Group, Madrid &amp; Barcelona, Barcelona, Spain</p>	<p>Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).</p>	Poster Session	Breast Cancer—Metastatic	<a href="https://meetinglibrary.asco.org/record/198275/abstract">https://meetinglibrary.asco.org/record/198275/abstract</a>
<p><b>Robert M. Rifkin, Jason M. Melear, Edward Faber</b>, William I. Bensinger, <b>John M. Burke, Mohit Narang</b>, Don A. Stevens, Kathleen Gray, Yana Lutska, Padma Bobba, Keqin Qi, Ming Qi, Thomas S. Lin, <b>Habte Aragaw Yimer</b>;</p> <p>US Oncology Research, Rocky Mountain Cancer Centers, Denver, CO; Texas Oncology—Austin, Austin, TX; Oncology Hematology Care, Inc., Cincinnati, OH; Swedish Cancer Institute, Seattle, WA; US Oncology Research, Rocky Mountain Cancer Centers, Aurora, CO; US Oncology Research, Maryland Oncology Hematology, Columbia, MD; Norton Health Care, Louisville, KY; Janssen Scientific Affairs, LLC, Horsham, PA; Janssen Research &amp; Development, LLC, Titusville, NJ; Janssen Research &amp; Development, LLC, Spring House, PA; US Oncology Research, Texas Oncology - Tyler, Tyler, TX</p>	<p>Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBORd) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.</p>	Poster Session	Hematologic Malignancies—Plasma Cell Dyscrasia	<a href="https://meetinglibrary.asco.org/record/195444/abstract">https://meetinglibrary.asco.org/record/195444/abstract</a>
<p>Gabrielle Betty Rocque, <b>Joanne Lorraine Blum</b>, Aldemar Montero, Meghan Sri Karuturi, Kenneth Manning, Lloyd Shabazz, Christopher Gallagher, Lara Zuberi, Joseph C Cappelleri, Marc Drucker, Yao Wang, Debu Tripathy;</p> <p>University of Alabama at Birmingham, Birmingham, AL; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; Gwinnett Medical Center, Lawrenceville, GA; The University of Texas MD Anderson Cancer Center, Houston, TX; Cape Fear Valley Medical Center, Fayetteville, NC; Delta Oncology Associates, Portsmouth, VA; MedStar Washington Hospital Center, Washington, DC; Henry Ford Hosp Michigan, Jacksonville, FL; Pfizer Inc, Groton, CT; ICON plc, San Francisco, CA; Pfizer Inc, New York, NY</p>	<p>Real-world quality of life (QoL) in black, indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from POLARIS.</p>	Poster Session	Breast Cancer—Metastatic	<a href="https://meetinglibrary.asco.org/record/198969/abstract">https://meetinglibrary.asco.org/record/198969/abstract</a>

Authors	Title	Presentation Type	Session	Link
<p>Guy Heinrich Maria Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A. Hurvitz, Shanu Modi, Fabrice Andre, Ian E. Krop, Xavier Gonzalez, Peter S. Hall, Benoit You, Cristina Saura, Sung-Bae Kim, <b>Cynthia R. C. Osborne</b>, Yasuaki Sagara, Eriko Tokunaga, Yali Liu, Jillian Cathcart, Caleb C. Lee, Christophe Perrin;</p> <p>Centre Hospitalier Universitaire du Sart Tilman Liège and Liège University, Liège, Belgium; Samsung Medical Center, Seoul, South Korea; Kanagawa Cancer Center, Yokohama, Japan; University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Memorial Sloan Kettering Cancer Center, New York, NY; Gustave Roussy, Université Paris-Sud, Villejuif, France; Dana-Farber Cancer Institute, Boston, MA; Instituto Oncológico Dr Rosell, Hospital General De Catalunya, SOLTI, Barcelona, Spain; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom; Medical Oncology Department, Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; US Oncology Research, McKesson Specialty Health, The Woodlands, TX; Texas Oncology, Baylor-Sammons Cancer Center, Dallas, TX; Hakuai Social Medical Corporation Sagara Hospital, Kagoshima, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; Daiichi Sankyo, Inc, Basking Ridge, NJ; Centre Eugène Marquis, Rennes, France</p>	<p>Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.</p>	Poster Session	Breast Cancer— Local/ Regional/Adjuvant	<a href="https://meetinglibrary.asco.org/record/198383/abstract">https://meetinglibrary.asco.org/record/198383/abstract</a>
<p><b>Joyce O'Shaughnessy</b>, Virginia G. Kaklamani, Yuan Yuan, Julie Barone, <b>Sami Diab</b>, Jennifer A. Crozier, Pat W. Whitworth, <b>Karen L. Tedesco</b>, Robert Maganini, Rakhshanda Layeequr Rahman, <b>Carlos A. Encarnacion</b>, Josien Haan, Amy Michelle Truitt, Andrea Menicucci, William Audeh, FLEX Investigators' Group;</p> <p>Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; University of Texas San Antonio MD Anderson Cancer Center, San Antonio, TX; City of Hope National Medical Center, Duarte, CA; Vail Health Shaw Regional Cancer Center, Edwards, CO; Rocky Mountain Cancer Center, US Oncology, Aurora, CO; Baptist MD Anderson Cancer Center, Jacksonville, FL; Nashville Breast Center, Nashville, TN; New York Oncology Hematology-Albany, US Oncology, Albany, NY; AMITA Health, Saint Alexis Medical Center, Bartlett, IL; Texas Tech University Health Sciences Center, Breast Center of Excellence, Amarillo, TX; Texas Oncology-Waco, US Oncology, Waco, TX; Research and Development, Agendia NV, Amsterdam, Netherlands; Medical Affairs, Agendia, Inc., Irvine, CA</p>	<p>Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature.</p>	Poster Session	Breast Cancer—Local/ Regional/Adjuvant	<a href="https://meetinglibrary.asco.org/record/198452/abstract">https://meetinglibrary.asco.org/record/198452/abstract</a>
<p>Cathy Graham, Douglas Kanter Marks, Nina D'Abreo, <b>Sami Diab</b>, Vijayakrishna K. Gadi, Midas Kuilman, Andrea Menicucci, Amy Michelle Truitt, Shiyu Wang, William Audeh, FLEX Investigators' Group;</p> <p>Emory University School of Medicine, Atlanta, GA; Perlmutter Cancer Center at NYU Langone Hospital-Long Island, Mineola, NY; Rocky Mountain Cancer Center, US Oncology, Aurora, CO; Fred Hutchinson Cancer Research Center, Seattle, WA; Research and Development, Agendia NV, Amsterdam, CA, Netherlands; Medical Affairs, Agendia, Inc., Irvine, CA</p>	<p>Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients &lt; 50 years and &gt; 50 years.</p>	Poster Session	Breast Cancer—Local/ Regional/Adjuvant	<a href="https://meetinglibrary.asco.org/record/198334/abstract">https://meetinglibrary.asco.org/record/198334/abstract</a>
<p>Rebecca Christian Arend, <b>Bradley J. Monk</b>, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Angeles Alvarez Secord, Ronnie Shapira-Frommer, Krishnansu Sujata Tewari, Tamar Rachmilewitz Minei, Dror Harats, Richard T. Penson;</p> <p>University of Alabama at Birmingham, Birmingham, AL; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ; University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati, OH; University College London Cancer Institute, London, United Kingdom; Stephenson Cancer Center, Oklahoma City, OK; Duke Cancer Institute, Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; The Division of Gynecologic Oncology at the University of California, Irvine, Orange, CA; Vascular Biogenics Ltd., Modiin, Israel; Harvard Medical School, Massachusetts General Hospital, Boston, MA</p>	<p>Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/ GOG-3018).</p>	Poster Session	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/201264/abstract">https://meetinglibrary.asco.org/record/201264/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada





Authors	Title	Presentation Type	Session	Link
<p>Katherine Cynthia Fuh, Michael A. Bookman, <b>Robert L. Coleman</b>, Thomas J Herzog, Premal H. Thaker, Joyce F. Liu, Michelle W. Lane, Reshma A. Rangwala, Gail McIntyre, <b>Bradley J. Monk</b>, Kathleen N. Moore;</p> <p>Washington University in St. Louis, St. Louis, MO; University of Arizona, Tucson, AZ; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX; Division of Gynecologic Oncology, The University of Cincinnati Cancer Institute, Cincinnati, OH; Department of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO; Dana-Farber Cancer Institute, Boston, MA; Aravive, Inc, Houston, TX; Merck &amp; Co., Inc., North Wales, PA; Aravive, Inc., Houston, TX; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ; Stephenson Cancer Center, Oklahoma City, OK</p>	<p>Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.</p>	Poster Session	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/197639/abstract">https://meetinglibrary.asco.org/record/197639/abstract</a>
<p>Melinda L. Telli, Jennifer Keating Litton, Joseph Thaddeus Beck, Jason M. Jones, <b>Jay Andersen</b>, Lida A. Mina, Raymond Brig, <b>Michael A. Danso</b>, Yuan Yuan, William Fraser Symmans, Antonello Abbattista, Kay Noonan, Marielena Mata, Douglas Laird, <b>Joanne Lorraine Blum</b>;</p> <p>Stanford University School of Medicine, Stanford, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Highlands Oncology Group, Springdale, AR; Avera Cancer Institute, Sioux Falls, SD; Compass Oncology, West Cancer Center, Tigard, OR; Banner MD Anderson Cancer Center, Gilbert, AZ; Brig Center for Cancer Care and Survivorship, Knoxville, TN; Virginia Oncology Associates, Norfolk, VA; City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Pfizer Oncology, Milan, Italy; Pfizer Inc., Groton, CT; Pfizer Inc., La Jolla, CA; Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX</p>	<p>Neoadjuvant talazoparib (TALA) in patients (pts) with germline <i>BRCA1/2</i> (<i>gBRCA1/2</i>) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor <i>BRCA</i> mutational status and zygosity and overall mutational landscape in a phase 2 study.</p>	Poster Session	Breast Cancer—Local/Regional/Adjuvant	<a href="https://meetinglibrary.asco.org/record/198385/abstract">https://meetinglibrary.asco.org/record/198385/abstract</a>
<p>R. Wendel Naumann, <b>Fadi S. Braiteh</b>, Lainie P. Martin, Erika P. Hamilton, <b>John Paul Diaz</b>, <b>Sami Diab</b>, Russell J. Schilder, John William Moroney, Denise Uyar, David M. O'Malley, Richard T. Penson, Clifford DiLea, Michael Palumbo, Venita I. De Almeida, Shannon L. Matheny, Lin Lu, Craig Jerome Berman, Arturo Molina;</p> <p>Levine Cancer Institute, Atrium Health, Charlotte, NC; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA; Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Miami Cancer Institute, Baptist Health, Miami, FL; Rocky Mountain Cancer Center, US Oncology, Aurora, CO; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; University of Chicago, Chicago, IL; Medical College of Wisconsin, Milwaukee, WI; The Ohio State University, Wexner Medical Center, Columbus, OH; Massachusetts General Hospital, Boston, MA; Aclairo Pharmaceutical Development Group, Vienna, VA; Sutro Biopharma, South San Francisco, CA</p>	<p>Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FR<math>\alpha</math>) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).</p>	Poster Session	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/197364/abstract">https://meetinglibrary.asco.org/record/197364/abstract</a>

Authors	Title	Presentation Type	Session	Link
<p>Lee S. Schwartzberg, Igor Bondarenko, Sara M. Tolaney, Andrew David Seidman, <b>Joyce O'Shaughnessy</b>, Yaroslav V. Shparyk, Chi-Feng Chung, Yen-Shen Lu, Nuria Chic, Lawrence C. Panasci, Yee Soo Chae, Sabela Recalde, Yevhen Hotko, Patricia Gomez, Gail Lynn Shaw Wright, Noshir Anthony Dacosta, Sina Vatandoust, Joseph P. O'Connell, Thomas Wei, Hope S. Rugo;</p> <p>West Cancer Center, Memphis, TN; City Clinical Hospital No4, Dnipro, Ukraine; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; Lviv State Oncological Regional Medical and Diagnostic Center, Lviv, Ukraine; Koo Foundation Sun Yat-sen Cancer Center, Taipei, Taiwan; National Taiwan University Hospital, Taipei, Taiwan; Hospital Clinic de Barcelona, Barcelona, Spain; Jewish General Hospital, Montreal, QC, Canada; Kyungpook National University Hospital, Daegu, South Korea; Institut Catala d'Oncologia Hospital Duran i Reynals, Barcelona, Spain; Uzhgorod National University, Uzhgorod, Ukraine; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Sarah Cannon Research Institute and Florida Cancer Specialists, New Port Richey, FL; North Shore Hematology Oncology Associates, Stonybrook, NY; Flinders Medical Centre, Flinders University, Adelaide, SA, Australia; Odonate Therapeutics, Inc., San Diego, CA; University of California, San Francisco, San Francisco, CA</p>	<p>Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.</p>	Poster Session	Breast Cancer—Metastatic	<a href="https://meetinglibrary.asco.org/record/198214/abstract">https://meetinglibrary.asco.org/record/198214/abstract</a>
<p>David Belada, Katerina Kopeckova, Juan Miguel Bergua, Marc André, Ernesto Perez Persona, Petra Pichler, Pia Klöpfer, Bettina Brackertz, Emanuel Lohrmann, Anirban Lahiry, Neha Shah, Wolfram Brugger, <b>John M. Burke</b>, Grzegorz S. Nowakowski;</p> <p>4th Department of Internal Medicine–Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic; Department of Oncology of the 2nd Faculty of Medicine of Charles University and University Hospital in Motol, Prague, Czech Republic; Hematology, Hospital San Pedro de Alcantara, Caceres, Spain; Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Bioaraba, [Onco-Hematology Research Group],Vitoria-Gasteiz, Spain, Osakidetza Basque Health Service, Araba University Hospital,[Hematology Department], Vitoria-Gasteiz, Spain; Department of Internal Medicine, University Hospital of St. Pölten, Karl Landsteiner University of Health Sciences, Karl Landsteiner Institute for Nephrology and Hemato Oncology, St. Pölten, Austria; MorphoSys AG, Planegg, Germany; US Oncology Research and Rocky Mountain Cancer Centers, Aurora, CO; Division of Hematology, Mayo Clinic, Rochester, MN</p>	<p>First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.</p>	Poster Session	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	<a href="https://meetinglibrary.asco.org/record/199020/abstract">https://meetinglibrary.asco.org/record/199020/abstract</a>
<p><b>Alexander I. Spira</b>, Frederick Hugh Wilson, Geoffrey Shapiro, Christophe Dooks, Alessandra Curioni-Fontecedro, Taito Esaki, Fabrice Barlesi, Kim Cocks, Andrew Trigg, Kendall Stevinson, Tara Matsuda, Qui Tran, Jhanelle Elaine Gray;</p> <p>US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Dana-Farber Cancer Institute, Boston, MA; UZ Gasthuisberg-Katholieke University Leuven, Leuven, Belgium; University Hospital of Zurich, Department of Oncology, Zurich, Switzerland; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; Gustave Roussy Cancer Center, Villejuif, France; Adelphi Values, Bollington, United Kingdom; Adelphi Values, Cheshire, United Kingdom; Amgen Inc., Thousand Oaks, CA; Amgen, Global Health Economics, Thousand Oaks, CA; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL</p>	<p>Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p. G12C mutated non-small cell lung cancer (NSCLC).</p>	Poster Session	Lung Cancer—Non-Small Cell Metastatic	<a href="https://meetinglibrary.asco.org/record/200635/abstract">https://meetinglibrary.asco.org/record/200635/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
<p>Debra L. Richardson, Erika P. Hamilton, Ana Oaknin, Leslie M. Randall, Susana N. Banerjee, Sara Kristina Taylor, Linda R. Mileskin, <b>Robert L. Coleman, Bradley J. Monk</b>, Mansoor Raza Mirza, Patricia Bernardo, Rebecca Mosher, Valerie Malyvanh Jansen, Antonella Savarese, Toon Van Gorp, Radoslaw Madry, Isabelle Laure Ray-Coquard, Nicole Concin;</p> <p>Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK; Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; University of California, Orange, CA; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom; BC Cancer-Kelowna, Kelowna, BC, Canada; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; US Oncology Research, The Woodlands, TX; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ; The Finsen Centre 5073, Copenhagen, Denmark; Mersana Therapeutics, Cambridge, MA; Mersana Therapeutics, Inc., Cambridge, MA; Vanderbilt University Medical Center, Nolensville, TN; Istituto Nazionale Tumori Regina Elena, Rome, Italy; BGOG &amp; Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Clinical Hospital of the Transfiguration of the Lord's Medical University Karol Marcinkowski, Poznań, Poland; GINECO, Lyon, France; Belgium and Luxembourg Gynaecological Oncology Group, University of Leuven, Leuven Cancer Institute, Leuven, Belgium</p>	<p>Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.</p>	Poster Session	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/201273/abstract">https://meetinglibrary.asco.org/record/201273/abstract</a>
<p>Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Johanna C. Bendell, <b>Timothy Larson, Allen Lee Cohn, Timothy K. Huyck, David Cosgrove</b>, Joseph A. Fiorillo, <b>Lawrence E. Garbo</b>, Shruthi Ravimohan, Von Potter, David D'Adamo, Neelesh Sharma, Ying A. Wang, Sabine Coppieters, Matthias Herpers, Carolina Soares Viana de Oliveira, <b>Andrew Scott Paulson</b>;</p> <p>City of Hope Comprehensive Cancer Center, Duarte, CA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Minnesota Oncology/The US Oncology Network, Minneapolis, MN; Rocky Mountain Cancer Center, Denver, CO; Nebraska Cancer Specialists, Omaha, NE; Division of Medical Oncology, Vancouver Cancer Center, Compass Oncology, Vancouver, WA; Willamette Valley Cancer Institute, Eugene, OR; New York Oncology Hematology, Albany, NY; Bristol-Myers Squibb, Lawrenceville, NJ; Bristol-Myers Squibb, New Haven, CT; Bayer HealthCare Pharmaceuticals, Whippany, NJ; Bayer HealthCare Pharmaceuticals, Cambridge, MA; Bayer AG, Diegem, Belgium; ClinStat GmbH, Cologne, Germany; Texas Oncology/The US Oncology Network, Dallas, TX</p>	<p>Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).</p>	Poster Session	Gastrointestinal Cancer—Colorectal and Anal	<a href="https://meetinglibrary.asco.org/record/196515/abstract">https://meetinglibrary.asco.org/record/196515/abstract</a>

Authors	Title	Presentation Type	Session	Link
<p>Ignace Vergote, <b>Bradley J. Monk, Robert L. Coleman</b>, Leslie M. Randall, Keiichi Fujiwara, Christian Marth, Linn Lena Woelber, Els Van Nieuwenhuysen, David Cibula, Paula Calvert, Ingrid Boere, Antonio González-Martín, Elsa Kalbacher, Nicoletta Colombo, Domenica Lorusso, Susana N. Banerjee, Fernando C. Maluf, Ibrahim Soumaoro, Brian M. Slomovitz;</p> <p>Belgium and Luxembourg Gynaecological Oncology Group (BCOG), University of Leuven, Leuven Cancer Institute, Leuven, Belgium; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; US Oncology Research, The Woodlands, TX; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; GOTIC and Saitama Medical University International Medical Center, Hidaka, Japan; Arbeitsgemeinschaft Gynäkologische Onkologie Austria (AGO-Austria), Medical University Innsbruck, Innsbruck, Austria; AGO &amp; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Central and Eastern European Gynecologic Oncology Group (CEGOG), Department of Obstetrics and Gynecology and First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; Cancer Trials Ireland, Dublin, Ireland; The Dutch Gynecology Oncology Group, Utrecht, Netherlands; GEICO and Clinica Universitaria de Navarra, Madrid, Spain; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens and CHRU Jean Minjoz, Besançon, France; University of Milan-Bicocca and European Institute of Oncology, IRCCS and Mario Negri Gynecologic Oncology Group (MANGO), Milan, Italy; Multicentre Italian Trials in Ovarian Cancer and Gynaecological Malignancies Group (MITO) and Scientific Directorate and Department of Women and Child Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; The National Cancer Research Institute (NCRI) and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Beneficência Portuguesa de São Paulo, São Paulo, Brazil; Genmab US, Inc, Plainsboro, NJ; Broward Health, Fort Lauderdale, FL</p>	<p>Tisotumab vedotin versus investigator's choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress).</p>	Poster Session	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/201277/abstract">https://meetinglibrary.asco.org/record/201277/abstract</a>
<p>Nancy L. Bartlett, <b>Christopher A. Yasechak</b>, Khaleel K. Ashraf, William N. Harwin, Robert Brownell Sims, Grzegorz S. Nowakowski;</p> <p>Division of Oncology, Washington University School of Medicine, St. Louis, MO; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Springfield, OR; Hematology and Oncology Associates of Alabama, Birmingham, AL; Sarah Cannon Research Institute, Fort Meyers, FL; Seagen Inc., Bothell, WA; Division of Hematology, Mayo Clinic, Rochester, MN</p>	<p>Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).</p>	Poster Session	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	<a href="https://meetinglibrary.asco.org/record/201299/abstract">https://meetinglibrary.asco.org/record/201299/abstract</a>
<p>Tomasz M. Beer, Charles H. McDonnell, Lincoln Nadauld, Minetta C. Liu, Eric A. Klein, <b>Robert Lawrence Reid</b>, Karen Chung, Margarita Lopatin, Eric T. Fung, Deborah Schrag;</p> <p>Knight Cancer Institute, Oregon Health &amp; Science University, Portland, OR; Sutter Health, Sacramento, CA; Intermountain Healthcare, St. George, UT; Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; US Oncology Research, Virginia Cancer Specialists, Fairfax, VA; GRAIL, Inc., Menlo Park, CA; Dana-Farber Cancer Institute, Boston, MA</p>	<p>A prespecified interim analysis of the PATHFINDER study: Performance of a multicancer early detection test in support of clinical implementation.</p>	Poster Session	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	<a href="https://meetinglibrary.asco.org/record/197724/abstract">https://meetinglibrary.asco.org/record/197724/abstract</a>
<p>Aditya Bardia, Javier Cortes, Sara A. Hurvitz, Suzette Delalogue, Hiroji Iwata, Shao Zhimin, Dheepak Kanagavel, Patrick Cohen, Qianying Liu, Sylvaine Cartot-Cotton, Vasiliki Pelekanou, <b>Joyce O'Shaughnessy</b>;</p> <p>Massachusetts General Hospital Cancer Center, Boston, MA; International Breast Cancer Center (IBCC), Barcelona, Spain; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Institute Gustave Roussy, Villejuif, France; Aichi Cancer Center Hospital, Nagoya, Japan; Fudan University, Shanghai, China; Sanofi, Vitry-Sur-Seine, France; Sanofi, Cambridge, MA; Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX</p>	<p>AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer.</p>	Poster Session	Breast Cancer—Metastatic	<a href="https://meetinglibrary.asco.org/record/201151/abstract">https://meetinglibrary.asco.org/record/201151/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
<p>Tony S. K. Mok, William E. Lawler, Merrill Kingman Shum, Shaker R. Dakhil, <b>Alexander I. Spira</b>, Fabrice Barlesi, Martin Reck, Marina Chiara Garassino, David R. Spigel, Delia Alvarez, Thian Kheoh, William Paxton, Richard C. Chao, Enriqueta Felip;</p> <p>State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong, China; Virginia K Crosson Cancer Center, Fullerton, CA; The Onc Inst of Hope and Innovation, Whittier, CA; NSABP/NRG Oncology, and Wichita NCORP via Christi Reg. Med. Ctr, Wichita, KS; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Aix-Marseille University, CEPCM CLIP, Assistance Publique Hôpitaux de Marseille, Marseille, France; LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Tracon Pharmaceuticals, Inc., San Diego, CA; Janssen Research and Development, LLC, San Diego, CA; Mirati Therapeutics, Inc., San Diego, CA; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain</p>	KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.	Poster Session	Lung Cancer—Non-Small Cell Metastatic	<a href="https://meetinglibrary.asco.org/record/201333/abstract">https://meetinglibrary.asco.org/record/201333/abstract</a>
<p>Manish Sharma, Richard D. Carvajal, Glenn J. Hanna, Bob T. Li, Kathleen N. Moore, Mark D. Pegram, Drew W. Rasco, <b>Alexander I. Spira</b>, Michael Alonso, Liang Fang, Amreen Husain, Edith A. Perez, Ecaterina Elena Dumbrava;</p> <p>START-Midwest, Grand Rapids, MI; Columbia University Irving Medical Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Stephenson Cancer Center, Oklahoma City, OK; Stanford Women's Cancer Center, Stanford, CA; START, San Antonio, TX; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Bolt Biotherapeutics, Redwood City, CA; F. Hoffmann-La Roche, Ltd., Basel, Switzerland; Mayo Clinic, Jacksonville, FL; The University of Texas MD Anderson Cancer Center, Houston, TX</p>	Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.	Poster Session	Developmental Therapeutics—Immunotherapy	<a href="https://meetinglibrary.asco.org/record/196087/abstract">https://meetinglibrary.asco.org/record/196087/abstract</a>
<p>Susana N. Banerjee, <b>Bradley J. Monk</b>, Els Van Nieuwenhuysen, Kathleen N. Moore, Ana Oaknin, Michel Fabbro, Nicoletta Colombo, David M. O'Malley, <b>Robert L. Coleman</b>, Jonathan A. Pachter, Andrew G. Koustenis, Gloria Patrick, Lorna Leonard, Rachel N. Grisham;</p> <p>The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ; UZ Leuven, Leuven, Belgium; Stephenson Cancer Center, Oklahoma City, OK; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; ICM Val d'Aurelle, Montpellier, France; European Institute of Oncology, Milan, Italy; The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH; University of Texas MD Anderson Cancer Center, Spring, TX; Verastem, Inc., Needham, MA; Verastem, Needham, MA; Institute of Cancer Research, Royal Cancer Hospital, London, United Kingdom; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY</p>	ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).	Poster Session	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/201286/abstract">https://meetinglibrary.asco.org/record/201286/abstract</a>
<p>Tom Stinchcombe, <b>Bradley J. Monk</b>, Alicia Frances Clare Okines, Paula R Pohlmann, Evan Y. Yu, Tanios S. Bekaii-Saab, Yoshiaki Nakamura, David M. O'Malley, Vicky Kang, Luke N. Walker, Martin Reck;</p> <p>Duke Cancer Institute, Durham, NC; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Division of Oncology, Department of Medicine, University of Washington, Seattle, WA; Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; The Ohio State University, The James Comprehensive Cancer Center, Columbus, OH; Seagen Inc., Bothell, WA; LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany</p>	SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).	Poster Session	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	<a href="https://meetinglibrary.asco.org/record/201141/abstract">https://meetinglibrary.asco.org/record/201141/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
<p>Ignace Vergote, Jose Alejandro Perez-Fidalgo, Erika P. Hamilton, Toon Van Gorp, Giorgio Valabrega, Annouschka Laenen, Amit M. Oza, Tally Levy, David Cibula, Jalid Sehoul, Eva Guerra, Hye Sook Chon, Alice Bergamini, Ignacio Romero, Dayana Michel, Jatin J. Shah, <b>Bradley J. Monk</b>, Brian M. Slomovitz, Mansoor Raza Mirza, Vicky Makker;</p> <p>Belgium and Luxembourg Gynaecological Oncology Group (BCOG), University of Leuven, Leuven Cancer Institute, Leuven, Belgium; Hospital Clínico Universitario de Valencia, INCLIVA, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, GEICAM Spanish Breast Cancer Group, Valencia, Spain; Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; BGOG &amp; Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Department of Oncology, University of Torino, Italy, Candiolo Cancer Institute, FPO - IRCCS, Torino, Italy; BGOG and Leuven Cancer Institute, Leuven, Belgium; Division of Medical Oncology and Hematology, University Health Network and Princess Margaret Cancer Centre, Toronto, ON, Canada; Division of Gynecologic Oncology, Wolfson Medical Center, Holon, Israel; First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic; Department of Gynecology With Center for Oncological Surgery, European Competence Center for Ovarian Cancer, Charité-Berlin University of Medicine, Berlin, Germany; Hospital Universitario Ramón y Cajal, Madrid, Spain; Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Obstet-Gynecol Dept, San Raffaele Scientific Institute, IRCCS, Milan, Italy; Instituto Valenciano de Oncología, Valencia, Spain; Karyopharm Therapeutics Inc., Newton, MA; GOG and Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; GOG and Gynecologic Oncology, Wertheim College of Medicine, Florida International University, Miami, FL; The Finsen Centre 5073, Copenhagen, Denmark; Memorial Sloan Kettering Cancer Center, New York, NY</p>	<p>SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.</p>	Poster Session	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/201284/abstract">https://meetinglibrary.asco.org/record/201284/abstract</a>
<p>Shom Goel, <b>Joyce O'Shaughnessy</b>, Antoinette R. Tan, Boris Milev Krastev, Hope S. Rugo, Philippe Georges Aftimos, Denise A. Yardley, Andric Zoran, Curt Douglas Wolfgang, Jessica Sorrentino, Wenli Tao, Andrew Paul Beelen, Rajesh K. Malik, Sarika Jain;</p> <p>Peter MacCallum Cancer Centre, Melbourne, Australia; Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; Levine Cancer Institute, Atrium Health, Charlotte, NC; MHAT for Women's Health, Nadezhda, Sofia, Bulgaria; University of California, San Francisco, San Francisco, CA; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Clinical Hospital Centre Bežanijska Kosa, Belgrade, Serbia; G1 Therapeutics, Inc., Research Triangle Park, NC</p>	<p>Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).</p>	Poster Session	Breast Cancer—Metastatic	<a href="https://meetinglibrary.asco.org/record/201140">https://meetinglibrary.asco.org/record/201140</a>
<p><b>Brandon Butler</b>, Nadaa Tayiab, Serra Phu, <b>Susan Nga Hoang</b>, <b>Brian Turnwald</b>, <b>Jody S. Garey</b>, <b>Bo He</b>, <b>John Russell Hoverman</b>;</p> <p>McKesson Corporation, The Woodlands, TX; McKesson, Scottsdale, AZ; GE Healthcare, Wauwatosa, WI; McKesson Specialty Health, The Woodlands, TX; US Oncology, Houston, TX; Texas Oncology/The US Oncology Network, Dallas, TX</p>	<p>A machine learning tool to predict mortality risk among patients with metastatic cancer in outpatient oncology care.</p>	Poster Session	Care Delivery and Regulatory Policy	<a href="https://meetinglibrary.asco.org/record/200121/abstract">https://meetinglibrary.asco.org/record/200121/abstract</a>
<p><b>Eric J. Clayton</b>, Imon Banerjee, <b>Patrick J. Ward</b>, <b>Maggie D Howell</b>, <b>Beth Lohmueller</b>, <b>Sunita Pierson</b>, <b>Rachel Hall</b>, <b>Peter B Harrison</b>, <b>David Michael Waterhouse</b>;</p> <p>Oncology Hematology Care, Cincinnati, OH; Emory University Hospital, Atlanta, GA; Onc Hem Care, Cincinnati, OH; Oncology Hematology Care, Inc., Cincinnati, OH; McKesson Corporation, The Woodlands, TX; Ontada, San Francisco, CA; US Oncology Research / Oncology Hematology Care (OHC), Inc., Cincinnati, OH</p>	<p>A natural language processing tool for automatic identification of new disease and disease progression: Parsing text in multi-institutional radiology reports to facilitate clinical trial eligibility screening.</p>	Poster Session	Care Delivery and Regulatory Policy	<a href="https://meetinglibrary.asco.org/record/200144/abstract">https://meetinglibrary.asco.org/record/200144/abstract</a>

Authors	Title	Presentation Type	Session	Link
<p><b>Lalan S. Wilfong</b>, Amila Patel, <b>Lance Ortega</b>, <b>Rhonda Boren</b>, Ben Pearson, <b>Terry Lynn Jensen</b>, <b>Holly Books</b>, <b>Kathryn Elizabeth Hudson</b>, <b>Debra A. Patt</b>;</p> <p>Texas Oncology/The US Oncology Network, Dallas, TX; Navigating Cancer, Seattle, WA; Texas Oncology PA, Dallas, TX; Texas Oncology, Dallas, TX; Texas Oncology, The US Oncology Network/McKesson Specialty Health, The Woodlands, TX; Duke University Medical Center, Durham, NC</p>	Improvement in incident resolution time with implementation of an electronic patient management solution at a community oncology practice.	Poster Session	Care Delivery and Regulatory Policy	<a href="https://meetinglibrary.asco.org/record/200131/abstract">https://meetinglibrary.asco.org/record/200131/abstract</a>
<p><b>Debra A. Patt</b>, <b>Lalan S. Wilfong</b>, <b>Kathryn Elizabeth Hudson</b>, Amila Patel, <b>Holly Books</b>, <b>Lance Ortega</b>, Ben Pearson, <b>Rhonda Boren</b>, Shrutika Patil, Kristin Olson-Celli, Ethan M. Basch;</p> <p>Texas Oncology, Dallas, TX; Texas Oncology/The US Oncology Network, Dallas, TX; Navigating Cancer, Seattle, WA; Texas Oncology PA, Dallas, TX; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC</p>	Implementation of electronic patient-reported outcomes for symptom monitoring in a large multi-site community oncology practice.	Poster Session	Symptoms and Survivorship	<a href="https://meetinglibrary.asco.org/record/200560/abstract">https://meetinglibrary.asco.org/record/200560/abstract</a>
<p>Sara A. Hurvitz, Haeseong Park, Sophia Frentzas, Catherine M. Shannon, Katharine Cuff, Richard Wilhelm Eek, George Thomas Budd, Amelia McCartney, <b>Joyce O'Shaughnessy</b>, Janice M. Lu, Jian Zhang, Dongmei Ji, Weina Shen, Matt Li, Jinchun Yan, Gang Xia, Yanping Ji, Sulan Yao, Gaozhun Xiong, Xichun Hu;</p> <p>David Geffen School of Medicine, University of California, Los Angeles/ Jonsson Comprehensive Cancer Center, Los Angeles, CA; Washington University School of Medicine in St. Louis, St. Louis, MO; Monash Hospital, Victoria, Australia; Mater Cancer Care Centre, South Brisbane, QLD, Australia; Princess Alexandra Hospital, Queensland, Australia; Border Medical Oncology, Wodonga, VIC, Australia; Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH; Monash Medical Centre, Clayton, VIC, Australia; Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Fudan University Shanghai Cancer Center, Shanghai, China; Ambrx, Inc, Princeton Junction, NJ; NovoCodex Biopharmaceuticals, Shaoxing, China; Ambrx, Inc., La Jolla, CA; Department of Medical Oncology, Fudan University Cancer Hospital, Shanghai, China</p>	Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpressing solid tumors: Results from two phase 1 clinical trials.	Poster Session	Breast Cancer—Metastatic	<a href="https://meetinglibrary.asco.org/record/197084/abstract">https://meetinglibrary.asco.org/record/197084/abstract</a>
<p>Sekwon Jang, John D. Powderly, <b>Alexander I. Spira</b>, Ouiam Bakkacha, Deryk Loo, Gerry C. Bohac, Manish Sharma;</p> <p>Inova Schar Cancer Institute, Fairfax, VA; Carolina BioOncology Institute, Huntersville, NC; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; MacroGenics, Inc., Rockville, MD; START-Midwest, Grand Rapids, MI</p>	Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.	Poster Session	Developmental Therapeutics—Immunotherapy	<a href="https://meetinglibrary.asco.org/record/196006/abstract">https://meetinglibrary.asco.org/record/196006/abstract</a>
<p>Raghad Muhsin Abdul-Karim, <b>Anthony W. Tolcher</b>, Shivaani Kummar, Manish R. Patel, <b>Alexander I. Spira</b>, Shekeab Jauhari, Maureen Duff, Rongda Xu, Ann Johnson, Anneleen Daemen, Pratik S. Multani, Edna Chow Maneval, Pamela N. Munster;</p> <p>NEXT Oncology, San Antonio, TX; Knight Cancer Institute, Oregon Health and Science University, Portland, OR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Florida Cancer Specialists / Sarah Cannon Research Institute, Lake Mary, FL; ORIC Pharmaceuticals, South San Francisco, CA; University of California San Francisco, San Francisco, CA</p>	Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.	Poster Session	Developmental Therapeutics—Immunotherapy	<a href="https://meetinglibrary.asco.org/record/200365/abstract">https://meetinglibrary.asco.org/record/200365/abstract</a>
<p>Johanna C. Bendell, <b>Alexander I. Spira</b>, Ramez Nassef Eskander, Ezra E.W. Cohen, Geoffrey Kuesters, Christopher Plescia, Karen Campbell, Tiffany Chen, Omid Hamid;</p> <p>Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; UC San Diego Moores Cancer Center, San Diego, CA; University of California, San Diego, San Diego, CA; Rubius Therapeutics, Cambridge, MA; The Angeles Clinic and Research Institute, Los Angeles, CA</p>	A phase 1 study of RTX-321, an engineered red blood cell as an artificial antigen-presenting cell expressing HLA-A*02 with the HPV-16 E7 peptide and 4-1BB ligand with membrane-bound IL-12 for the treatment of HPV 16-positive cancers.	Poster Session	Developmental Therapeutics—Immunotherapy	<a href="https://meetinglibrary.asco.org/record/201192/abstract">https://meetinglibrary.asco.org/record/201192/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
<p><b>Andrew Scott Paulson</b>, Daneng Li, Max W. Sung, Christopher Tucci, John S. Kauh, Shivani Nanda, Marek K. Kania, Arvind Dasari;</p> <p>Texas Oncology/The US Oncology Network, Dallas, TX; City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Tisch Cancer Institute at Mount Sinai, New York, NY; Hutchison MediPharma, Florham Park, NJ; Hutchison MediPharma (US) Inc., Florham Park, NJ; Hutchison MediPharma International Inc, Florham Park, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX</p>	Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs).	Poster Session	Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary	<a href="https://meetinglibrary.asco.org/record/199403/abstract">https://meetinglibrary.asco.org/record/199403/abstract</a>
<p>Shannon Neville Westin, Siqing Fu, Apostolia Maria Tsimberidou, Sarina Anne Anne Piha-Paul, Fechukwu Akhmedzhanov, Bulent Yilmaz, Lacey McQuinn, Amanda L. Brink, Jing Gong, Cheuk Hong Leung, Heather Y. Lin, David S. Hong, Shubham Pant, Amir A. Jazaeri, David Marc Gershenson, Anil K. Sood, <b>Robert L. Coleman</b>, Jatin J. Shah, Funda Meric-Bernstam, Aung Naing;</p> <p>The University of Texas MD Anderson Cancer Center, Houston, TX; US Oncology Research, The Woodlands, TX; Karyopharm Therapeutics Inc., Newton, MA</p>	Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.	Poster Session	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/197350">https://meetinglibrary.asco.org/record/197350</a>
<p>Toon Van Gorp, Mansoor Raza Mirza, Alain Lortholary, David Cibula, Axel Walther, Antonella Savarese, Maria Pilar Barretina-Ginesta, Firat Ortaç, Christos Papadimitriou, Lubomir Bodnar, Chyong-Huey Lai, Jacob Korach, Christian Marth, Kosei Hasegawa, Xing Xie, Emma L. Barber, <b>Robert L. Coleman</b>, Stephen Michael Keefe, Robert Orłowski, Brian Slomovitz;</p> <p>UZ Leuven, Leuven, Belgium; NSGO-CTU &amp; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Centre Catherine de Sienne, Hôpital Privé du Confluent, Nantes, France; Department of Obstetrics and Gynecology, General Faculty Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic; Bristol Cancer Institute, University Hospitals Bristol, Bristol, United Kingdom; Istituto Nazionale Tumori Regina Elena, Rome, Italy; Catalan Institute of Oncology and Girona Biomedical Research Institute, Medical School University of Girona, Girona, Spain; Ankara University School of Medicine, Ankara, Turkey; Aretaieio University Hospital, National and Kapodistrian University of Athens, Athens, Greece; Department of Oncology and Immunooncology, Warmian-Masurian Cancer Center of the Ministry of the Interior and Administration's Hospital, Olsztyn, Poland; TGOG and Department of Gynecology and Obstetrics, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan; Gynecologic Oncology Department, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Obstetrics and Gynecology, Medizinische Universität Innsbruck, Innsbruck, Austria; Department of Gynecologic Oncology, Saitama Medical University, Hidaka, Saitama Prefecture, Japan; Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China; Northwestern University Feinberg School of Medicine, Chicago, IL; US Oncology Research, The Woodlands, TX; Merck &amp; Co., Inc., Kenilworth, NJ; Broward Health, Fort Lauderdale, FL</p>	ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.	Poster Session	Gynecologic Cancer	<a href="https://meetinglibrary.asco.org/record/201207/abstract">https://meetinglibrary.asco.org/record/201207/abstract</a>
<p>Funda Meric-Bernstam, <b>Alexander I. Spira</b>, Aaron Elliott Lisberg, Jacob Sands, Noboru Yamamoto, Melissa Lynne Johnson, Kiyotaka Yoh, Edward B. Garon, Rebecca Suk Heist, Adam Petrich, Jonathan Greenberg, Naoyuki Tajima, Yui Kawasaki, Jessie Gu, Fumiaki Kobayashi, Yasong Lu, Ferdinand M. Guevara, Toshio Shimizu;</p> <p>The University of Texas MD Anderson Cancer Center, Houston, TX; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA; Dana-Farber Cancer Institute, Boston, MA; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; Sarah Cannon Research Institute, Nashville, TN; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa-Shi, Chiba, Japan; University of California, Los Angeles, Los Angeles, CA; Massachusetts General Cancer Center, Boston, MA; Daiichi Sankyo, Basking Ridge, NJ; Daiichi Sankyo Co., Ltd, Tokyo, Japan</p>	TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).	Poster Session	Lung Cancer—Non-Small Cell Metastatic	<a href="https://meetinglibrary.asco.org/record/200486/abstract">https://meetinglibrary.asco.org/record/200486/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada





Authors	Title	Presentation Type	Session	Link
Zofia Piotrowska, Helena Alexandra Yu, James Chih-Hsin Yang, Marianna Koczywas, Egbert F. Smit, Daniel Shao-Weng Tan, Victor Ho-Fun Lee, Ross A. Soo, John M. Wrangle, <b>Alexander I. Spira</b> , Vamsidhar Velcheti, Mark A. Socinski, Asher Page, David Witter, Leigh Zawel, Jon M. Wigginton, Myles Steven Clancy, Danny Nguyen;  Massachusetts General Hospital, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan; City of Hope National Medical Center, Duarte, CA; Netherlands Cancer Institute, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Queen Mary Hospital, The University of Hong Kong, Hong Kong, China; National University Hospital, Singapore, Singapore; Medical University of South Carolina, Charleston, SC; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; NYU Langone, Perlmutter Cancer Center, New York, NY; Advent Health Hematology and Oncology, Orlando, FL; Cullinan-Pearl, Cambridge, MA; Pacific Shores Medical Group, Long Beach, CA	Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).	Poster Session	Lung Cancer—Non-Small Cell Metastatic	<a href="https://meetinglibrary.asco.org/record/200580/abstract">https://meetinglibrary.asco.org/record/200580/abstract</a>
Kiyotaka Yoh, Yasushi Goto, Michael Thomas, <b>Alexander I. Spira</b> , Jacob Sands, Melissa Lynne Johnson, Jonathan Greenberg, Adam Matthew Petrich, Ferdinand M. Guevara, Penny Phillips, Ekaterine Alexandris, Jessie Gu, Yong Zhang, Dale Edward Shuster, Aaron Elliott Lisberg;  Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa-Shi, Chiba, Japan; National Cancer Center Hospital, Tokyo, Japan; Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; Daiichi Sankyo, Basking Ridge, NJ; UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA	A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).	Poster Session	Lung Cancer—Non-Small Cell Metastatic	<a href="https://meetinglibrary.asco.org/record/201325/abstract">https://meetinglibrary.asco.org/record/201325/abstract</a>
Mark A. Socinski, <b>Alexander I. Spira</b> , Luis G. Paz-Ares, Martin Reck, Shun Lu, Makoto Nishio, Jiang Li, Yunfei Zhou, Joon Whan Rhee, Sandra Chica Duque, Xinmin Yu;  Advent Health Hematology and Oncology, Orlando, FL; Virginia Cancer Specialists, US Oncology Research. The US Oncology Network, New York University, Fairfax, VA; Department of Medical Oncology, Hospital Universitario 12 De Octubre, Madrid, Spain; Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany; Shanghai Chest Hospital, Shanghai, China; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; BeiGene (US) Co., Ltd., San Mateo, CA; Department of Medical Oncology, Cancer Hospital of University of Chinese Academy of Sciences & Zhejiang Cancer Hospital, Hangzhou, China	AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).	Poster Session	Lung Cancer—Non-Small Cell Metastatic	<a href="https://meetinglibrary.asco.org/record/201342/abstract">https://meetinglibrary.asco.org/record/201342/abstract</a>
<b>Eric S. Nadler, Anupama Vasudevan, Kalatu Davies, Yunfei Wang</b> , Ravindra Gupta, Sarika Ogale;  Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX; Ontada, The Woodlands, TX; Genentech, South San Francisco, CA”	Real-world patterns of biomarker testing and targeted therapy in metastatic non-small cell lung cancer (mNSCLC) in the community oncology setting.	Poster Session	Lung Cancer—Non-Small Cell Metastatic	<a href="https://meetinglibrary.asco.org/record/200607/abstract">https://meetinglibrary.asco.org/record/200607/abstract</a>
<b>Eric S. Nadler, Anupama Vasudevan, Kalatu Davies, Yunfei Wang</b> , Ann Johnson, Sarika Ogale;  Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX; Ontada, The Woodlands, TX; Genentech, South San Francisco, CA”	Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).	Poster Session	Lung Cancer—Non-Small Cell Local-Regional/SmallCell/Other Thoracic Cancers	<a href="https://meetinglibrary.asco.org/record/198685/abstract">https://meetinglibrary.asco.org/record/198685/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
<p>Chung-Han Lee, Amishi Yogesh Shah, James J Hsieh, Arpit Rao, Alvaro Pinto, Mehmet Asim Bilen, <b>Allen Lee Cohn</b>, <b>Christopher DiSimone</b>, <b>David R. Shaffer</b>, Regina Gironés Sarrió, Sara Gunnestad Ribe, Jane Wu, Emmett V. Schmidt, Peter Kubiak, Chinyere Okpara, Alan D. Smith, Robert J. Motzer;</p> <p>Memorial Sloan Kettering Cancer Center, New York, NY; Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX; Department of Medicine, Oncology Division, Washington University School of Medicine, St. Louis, MO; Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio, TX; Servicio de Oncología, Hospital Universitario La Paz, Madrid, Spain; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Medical Oncology, US Oncology Research, Rocky Mountain Cancer Center, Denver, CO; Medical Oncology/Hematology, Arizona Oncology Associates, Tucson, AZ; Medical Oncology, US Oncology Research, New York Oncology Hematology, Albany, NY; Medical Oncology Service, Hospital Universitari i Politècnic la FE, Valencia, Spain; Medical Oncology, Sorlandet Hospital Kristiansand, Kristiansand, Norway; Biostatistics, Eisai Inc., Woodcliff Lake, NJ; Clinical Research, Merck &amp; Co., Inc., Kenilworth, NJ; Clinical Research, Eisai Inc., Woodcliff Lake, NJ; Clinical Research, Eisai Ltd., Hatfield, United Kingdom; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</p>	<p>Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.</p>	Publication Only	Publication Only: Genitourinary Cancer—Kidney and Bladder	<a href="https://meetinglibrary.asco.org/record/197775/abstract">https://meetinglibrary.asco.org/record/197775/abstract</a>
<p>Patricia A. Robinson, Michaela L. Tsai, Shelly S. Lo, June Lee, <b>Matei P. Socoteanu</b>, Heather Kling, Michelle Bolner, Lisa Eileen Blumencranz, William Audeh;</p> <p>Loyola University Chicago, Stritch School of Medicine, Maywood, IL; Minnesota Oncology Hematology, Minneapolis, MN; Breast Specialists of South Florida, Atlantis, FL; Texas Oncology-Longview Cancer Center, US Oncology, Longview, TX; Medical Affairs, Agendia, Inc., Irvine, CA; Medical Affairs, Agendia Inc., Irvine, CA</p>	<p>Genomic risk classification by the 70-gene signature and 21-gene assay in African American early-stage breast cancer patients.</p>	Publication Only	Publication Only: Breast Cancer—Local/Regional/Adjuvant	<a href="https://meetinglibrary.asco.org/record/200985/abstract">https://meetinglibrary.asco.org/record/200985/abstract</a>
<p>John E. Godwin, Bassam Ibrahim Mattar, Michael B. Maris, Carlos R. Bachier, Don A. Stevens, Daanish Hoda, Juan Carlos Varela, Mohamad Cherry, Suzanne R. Fanning, <b>James H. Essell</b>, <b>Habte Aragaw Yimer</b>, Jay G. Courtright, <b>Jeff Porter Sharman</b>, Nikolaus S. Trede, Marina Youssef, James Lymp, Paul Shaughnessy;</p> <p>Providence Medical Group, Portland, OR; Cancer Ctr of Kansas PA, Wichita, KS; Rocky Mountain Blood and Marrow Transplant Program, Denver, CO; Texas Transplant Physician Group PLLC, San Antonio, TX; Louisville Onc, Louisville, KY; Intermountain Healthcare, Sandy, UT; Johns Hopkins Med Inst, Baltimore, MD; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Prisma Health, Greenville, SC; Oncology/Hematology Care, Inc, Cincinnati, OH; Texas Oncology-Tyler, Tyler, TX; Texas Oncology-Dallas, Dallas, TX; Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, OR; Bristol-Myers Squibb, Seattle, WA; Bristol Myers Squibb, Princeton, NJ; Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA; Sarah Cannon-Methodist Healthcare System, San Antonio, TX</p>	<p>Outreach: Preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the nonuniversity setting.</p>	Publication Only	Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	<a href="https://meetinglibrary.asco.org/record/199930/abstract">https://meetinglibrary.asco.org/record/199930/abstract</a>
<p>Laura Lasiter, Shrujal Baxi, Andrew J. Belli, Marley Boyd, Jennifer Christian, Aaron B. Cohen, Janet L Espirito, Liz Garrett-Mayer, Eric Hansen, Monika A. Izano, Yanina Natanzon, Donna Rivera, <b>Nicholas J. Robert</b>, Mackenzie Small, Connor Sweetnam, Olga Tymejczyk, Joseph Wagner, Jeff Allen;</p> <p>Friends of Cancer Research, Washington, DC; Flatiron Health, New York, NY; COTA, Inc., Boston, MA; McKesson Life Sciences, The Woodlands, TX; IQVIA, Research Triangle Park, NC; Ontada, Irving, TX; American Society of Clinical Oncology, Alexandria, VA; Syapse, San Francisco, CA; ConcertAI, Boston, MA; U.S. Food and Drug Administration, Silver Spring, MD; US Oncology, The Woodlands, TX; IQVIA, Durham, NC</p>	<p>Evaluating real-world overall survival (rwOS) across oncology data sources: Friends of Cancer Research non-small cell lung cancer pilot study.</p>	Publication Only	Publication Only: Health Services Research and Quality Improvement	<a href="https://meetinglibrary.asco.org/record/199079/abstract">https://meetinglibrary.asco.org/record/199079/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
Michael S. Broder, Sikander Ailawadhi, Himisha Beltran, L. Johnetta Blakely, George Thomas Budd, Laurie Carr, Michael Cecchini, Patrick Wayne Cobb, Sarah N. Gibbs, Anuraag Kansal, Ashley Kim, <b>Bradley J. Monk</b> , Lee S. Schwartzberg, Deborah J.L. Wong, Irina Yermilov;  Partnership for Health Analytic Research, LLC, Beverly Hills, CA; Mayo Clinic, Jacksonville, FL; Dana Farber Cancer Institute, Boston, MA; Tennessee Oncology, Nashville, TN; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; National Jewish Health, Denver, CO; Yale University, New Haven, CT; SCL Health, Billings, MT; GRAIL, Inc., Menlo Park, CA; Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ; West Cancer Center, Memphis, TN; UCLA Health, Los Angeles, CA	Estimates of stage-specific preclinical sojourn time across 21 cancer types.	Publication Only	Publication Only: Health Services Research and Quality Improvement	<a href="https://meetinglibrary.asco.org/record/199863/abstract">https://meetinglibrary.asco.org/record/199863/abstract</a>
<b>Robert Lawrence Reid, Yiqiong Xie, Junxin Shi</b> , Katrine L Wallace;  US Oncology, Virginia Cancer Specialists, Fairfax, VA; Ontada, The Woodlands, TX; Clovis Oncology, Inc., Boulder, CO	Real-world data analysis of the utilization of second-line maintenance therapy for patients with advanced ovarian cancer.	Publication Only	Publication Only: Health Services Research and Quality Improvement	<a href="https://meetinglibrary.asco.org/record/199468/abstract">https://meetinglibrary.asco.org/record/199468/abstract</a>
Florence Marteau, Brooke Harrow, Christine McCarthy, Joel Wallace, Alisha Monnette, Yunfei Wang, <b>Gurjot K. Doshi</b> ;  IPSEN Pharma SAS, Boulogne-Billancourt Cedex, France; Ipsen Inc, Cambridge, MA; Ipsen, Boulogne-Billancourt, Ile De France, France; Exelixis, Alameda, CA; McKesson, The Woodlands, TX; US Oncology Research, McKesson Specialty Health, The Woodlands, TX; US Oncology, Houston, TX	Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with mRCC.	Publication Only	Publication Only: Genitourinary Cancer—Kidney and Bladder	<a href="https://meetinglibrary.asco.org/record/198012/abstract">https://meetinglibrary.asco.org/record/198012/abstract</a>
Barbara Stewart Schwartzberg, <b>Kathryn T. Howell</b> , Joyce A Moore, <b>Devchand Paul</b> ;  Schwartzberg Center for Minimally Invasive Breast Surgery, Santa Rosa, CA; Radiation Oncology at Rocky Mountain Cancer Centers, Littleton, CO; Western Surgical Care, P.C., Lone Tree, CO; US Oncology Research, and Rocky Mountain Cancer Centers, Denver, CO	ASTRO suitability criteria assessment in early-stage breast cancer patients treated with intraoperative radiation therapy (IORT) plus 21 gene recurrence score (RS) assay result guided adjuvant medical therapy.	Publication Only	Publication Only: Breast Cancer—Local/Regional/Adjuvant	<a href="https://meetinglibrary.asco.org/record/200788/abstract">https://meetinglibrary.asco.org/record/200788/abstract</a>
<b>Charles Lance Cowey</b> , Chieh-I Chen, Kathleen M. Aguilar, <b>Kalatu Davies</b> , Patrick R. LaFontaine, Matthew G. Fury, Timothy Geoffrey Bowler, Jessica J. Jalbert, Asieh Golozar;  Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX; Regeneron Pharmaceuticals, Inc., Tarrytown, NY; Ontada, The Woodlands, TX; Sanofi, Cambridge, MA”	Outcomes in patients (pts) with advanced basal cell carcinoma (aBCC) who discontinued hedgehog inhibitors (HHI) as first-line (1L) systemic treatment (Tx) in a U.S. community oncology setting: A retrospective observational study.	Publication Only	Publication Only: Health Services Research and Quality Improvement	<a href="https://meetinglibrary.asco.org/record/199201/abstract">https://meetinglibrary.asco.org/record/199201/abstract</a>
<b>Charles Lance Cowey</b> , Chieh-I Chen, <b>Kathleen M. Aguilar, Kalatu Davies</b> , Patrick R. LaFontaine, Matthew G. Fury, Timothy Geoffrey Bowler, Asieh Golozar, Jessica J. Jalbert;  Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX; Regeneron Pharmaceuticals, Inc., Tarrytown, NY; Ontada, The Woodlands, TX; Sanofi,”	Frequency, characteristics, and subsequent treatment (Tx) of real-world patients (pts) who discontinue hedgehog inhibitors (HHIs) as first-line (1L) systemic Tx for advanced basal cell carcinoma (aBCC).	Publication Only	Publication Only: Health Services Research and Quality Improvement	<a href="https://meetinglibrary.asco.org/record/199597/abstract">https://meetinglibrary.asco.org/record/199597/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



Authors	Title	Presentation Type	Session	Link
<b>Robert Lawrence Reid, Yiqiong Xie, Junxin Shi,</b> Katrine L Wallace; US Oncology, Virginia Cancer Specialists, Fairfax, VA; Ontada, The Woodlands, TX; Clovis Oncology, Inc., Boulder, CO”	Real-world data analysis of the utilization of second-line maintenance therapy for patients with advanced ovarian cancer.	Publication Only	Publication Only: Health Services Research and Quality Improvement	<a href="https://meetinglibrary.asco.org/record/199468/abstract">https://meetinglibrary.asco.org/record/199468/abstract</a>
Nabil F. Saba, Soham Shukla, <b>Kathleen M. Aguilar,</b> Marc S. Ballas, Kelly Bell, <b>Marley Boyd,</b> Jessica Chao, Catherine Elizabeth Ellis, Kelesitse Phiri, <b>Wan-Yu Tseng, Eric S. Nadler;</b> Winship Cancer Institute, Emory University, Atlanta, GA; GlaxoSmithKline, Collegeville, PA; Ontada, The Woodlands, TX; Texas Oncology, Dallas, TX”	Evolution of standard of care therapies used for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A real-world analysis of patient health records from 2016 to 2019.	Publication Only	Publication Only: Health Services Research and Quality Improvement	<a href="https://meetinglibrary.asco.org/record/199909/abstract">https://meetinglibrary.asco.org/record/199909/abstract</a>

**Bolded text:** Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada



**Learn More**

usoncology.com  
researchopportunities@mckesson.com  
**281.863.1000**

©2021 McKesson Corporation. All rights reserved.  
USON-1039019-05-21

